Tammy L. S. Benzinger

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

The recent approval of disease-modifying therapies for symptomatic Alzheimer's disease is a major advance for a condition with few therapeutic options. Anti-amyloid monoclonal antibodies have shown clinically meaningful benefits in slowing cognitive decline. Clinical trials in symptomatic Alzheimer's disease suggest th...